Evidence map›Paper›PMID 35261785›Full record

ArticleAmerican journal of cancer research2022

AHRR contributes to inflammatory lymphangiogenesis by activating the EPAS1/VEGFD signaling axis in head and neck cancer.

An Hu, Jian-Wei Zhang, Li-Yun Yang, Pei-Pei Qiao, Dan Lu

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

An HuDepartment of Otolaryngology-Head and Neck Surgery, Gongli Hospital, Second Military Medical University Pudong New Area, Shanghai 200135, China.
Jian-Wei ZhangDepartment of Otolaryngology-Head and Neck Surgery, Gongli Hospital, Second Military Medical University Pudong New Area, Shanghai 200135, China.
Li-Yun YangDepartment of Otolaryngology-Head and Neck Surgery, Gongli Hospital, Second Military Medical University Pudong New Area, Shanghai 200135, China.
Pei-Pei QiaoDepartment of Otolaryngology-Head and Neck Surgery, Gongli Hospital, Second Military Medical University Pudong New Area, Shanghai 200135, China.
Dan LuDepartment of Otolaryngology-Head and Neck Surgery, Gongli Hospital, Second Military Medical University Pudong New Area, Shanghai 200135, China.
Second Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymph node metastasis (LNM) is associated with poor survival in patients with Head and Neck cancer (HNC). Aryl hydrocarbon receptor repressor (AHRR) is thought to be responsible for increased lymphangiogenesis and LNM. AHRR and endothelial PAS domain-containing protein 1 (EPAS1) are basic helix-loop-helix/per-arnt-sim family transcription factors, however, its central role in lymphangiogenesis remains to be explored. In this study, we explored that EPAS1 dimerizes with HIF-1β during lymphangiogenes and tumor growth, inducing expression of many genes, including vascular endothelial growth factor-d (VEGFD). AHRR wild-type (

Indexed as

AHRREPAS1head and neck cancerHIF-1βlymphangiogenesis

Identifiers

PMID35261785
PMCPMC8899997
OpenAlexW4226153386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.